METHODS OF DETECTING CANCER WITH ANTIBODIES TO CYTOKINE RECEPTOR ZCYTOR19

• US 20070117165A1
• Filed: 10/06/2006
• Published: 05/24/2007
• Est. Priority Date: 11/28/2000
• Status: Active Grant

• Current Assignee: Airbus Operations Limited (Airbus SE)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Xu, Wenfeng, Grant, Francis, Whitmore, Theodore, Presnell, Scott, Novak, Julia
• Granted Patent: US 7,618,791 B2
• Time in Patent Office: Days
• US Class Current: 435/7.230
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/715 for cytokines; for lymphokines; for interferons
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Claims

1. A method for detecting a cancer in a patient, comprising:

obtaining a tissue or biological sample from a patient;

incubating the tissue or biological sample with an antibody that specifically binds to the polypeptide of;

(a) the amino acid sequence as shown in SEQ ID NO;

2 from amino acid number 21 (Arg) to amino acid number 223 (Pro);

(b) the amino acid sequence as shown in SEQ ID NO;

2 from amino acid number 21 (Arg) to amino acid number 226 (Asn);

(c) the amino acid sequence as shown in SEQ ID NO;

2 from amino acid number 21 (Arg) to amino acid number 249 (Trp);

(d) the amino acid sequence as shown in SEQ ID NO;

2 from amino acid number 250 (Lys) to amino acid number 491 (Arg);

(e) the amino acid sequence as shown in SEQ ID NO;

19 from amino acid number 250 (Lys) to 520 (Arg);

(f) the amino acid sequence as shown in SEQ ID NO;

2 from amino acid number 21 (Arg) to amino acid number 491 (Arg);

(g) the amino acid sequence as shown in SEQ ID NO;

19 from amino acid number 21 (Arg) to amino acid number 520 (Arg);

(h) the amino acid sequence as shown in SEQ ID NO;

2 from amino acid number 1 (Met) to amino acid number 491 (Arg);

(i) the amino acid sequence as shown in SEQ ID NO;

19 from amino acid number 1 (Met) to amino acid number 520 (Arg);

(j) the amino acid sequence as shown in SEQ ID NO;

21 from amino acid number 21 (Arg) to amino acid number 163 (Trp);

(k) the amino acid sequence as shown in SEQ ID NO;

21 from amino acid number 21 (Arg) to amino acid number 211 (Ser); and

(l) the amino acid sequence as shown in SEQ ID NO;

21 from amino acid number 1 (Met) to amino acid number 211 (Ser);

under conditions wherein the antibody binds to its complementary polypeptide in the tissue or biological sample;

visualizing the antibody bound in the tissue or biological sample; and

comparing levels of antibody bound in the tissue or biological sample from the patient to a normal control tissue or biological sample,

wherein an increase in the level of antibody bound to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of a cancer in the patient.